Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.
Amphetamine
/ therapeutic use
Central Nervous System Stimulants
/ therapeutic use
Cocaine
/ therapeutic use
Double-Blind Method
Humans
Lisdexamfetamine Dimesylate
/ therapeutic use
Methylphenidate
/ therapeutic use
Modafinil
/ therapeutic use
Prescription Drugs
/ therapeutic use
Randomized Controlled Trials as Topic
/ methods
Substance-Related Disorders
/ diagnosis
Treatment Outcome
Agonist
Amphetamine
Cocaine
Methamphetamine
Methylphenidate
Modafinil
Prescription psychostimulants
Psychostimulants
Replacement
Substance use disorders
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
08
02
2020
accepted:
18
05
2020
pubmed:
1
7
2020
medline:
5
11
2020
entrez:
1
7
2020
Statut:
ppublish
Résumé
Agonist-based pharmacologic intervention is an accepted approach in treatment of opioid and tobacco use disorders. We conducted a systematic review and meta-analysis to evaluate usefulness of an agonist approach as treatment of (psycho)stimulant use disorder (PSUD). We reviewed PubMed/Medline, LILACS, and ClinicalTrials.gov databases searching for randomized, double-blind, placebo-controlled, parallel-design studies evaluating outcomes of individuals treated for cocaine- or amphetamine-type substance use disorder. We combined results of all trials that included the following prescription psychostimulants (PPs): modafinil, methylphenidate, or amphetamines (mixed amphetamine salts, lisdexamphetamine, and dextroamphetamine). The combined sample consisted of 2889 patients. Outcomes of interest included the following: drug abstinence (defined as 2-3 weeks of sustained abstinence and the average maximum days of consecutive abstinence), percentage of drug-negative urine tests across trial, and retention in treatment. We conducted random-effects meta-analyses and assessed quality of evidence using the GRADE system. Thirty-eight trials were included. Treatment with PPs increases rates of sustained abstinence [risk ratio (RR) = 1.45, 95% confidence interval (CI) = (1.10, 1.92)] and duration of abstinence [mean difference (MD) = 3.34, 95% CI = (1.06, 5.62)] in patients with PSUD, particularly those with cocaine use disorder (very low-quality evidence). Prescription amphetamines were particularly efficacious in promoting sustained abstinence in patients with cocaine use disorder [RR = 2.44, 95% CI = (1.66, 3.58)], and higher doses of PPs were particularly efficacious for treatment of cocaine use disorder [RR = 1.95, 95% CI = (1.38, 2.77)] (moderate-quality evidence). Treatment with prescription amphetamines also yielded more cocaine-negative urines [MD = 8.37%, 95% CI = (3.75, 12.98)]. There was no effect of PPs on the retention in treatment. Prescription psychostimulants, particularly prescription amphetamines given in robust doses, have a clinically significant beneficial effect to promote abstinence in the treatment of individuals with PSUD, specifically the population with cocaine use disorder.
Identifiants
pubmed: 32601988
doi: 10.1007/s00213-020-05563-3
pii: 10.1007/s00213-020-05563-3
doi:
Substances chimiques
Central Nervous System Stimulants
0
Prescription Drugs
0
Methylphenidate
207ZZ9QZ49
Amphetamine
CK833KGX7E
Cocaine
I5Y540LHVR
Modafinil
R3UK8X3U3D
Lisdexamfetamine Dimesylate
SJT761GEGS
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM